Biologit, founded in 2021 by Nicole Baker and Bruno Ohana, is a Dublin-based company specialising in automating the monitoring of scientific literature, particularly in the field of pharmacovigilance. The company aims to assist life sciences firms in automating safety monitoring, particularly in the detection of adverse events related to drugs from development to post-market. Baker, an immunologist and Ohana, a tech expert, co-founded Biologit with the goal of leveraging AI to simplify the detection of adverse events and enhance patient safety.
Biologit’s flagship product Biologit MLM-AI is designed to automate the comprehensive and time-consuming task of monitoring scientific literature. The platform, developed in collaboration with domain experts, includes a vast scientific literature database with over 45 million citations that is continuously growing. The database allows users to run searches seamlessly, reducing friction and costs in the monitoring process.
The company’s roots are in Trinity College Dublin, where the technology was initially incubated. Biologit participated in Enterprise Ireland’s New Frontiers Entrepreneur Development Programme and Baker was involved in Big Ideas 2020. The company’s first product, Biologit MLM-AI, was developed through iterative processes with early adopters to meet the industry’s needs.
Biologit has been focused on customer acquisition and growth since the launch of MLM-AI, aiming to build a global user base. The company, after a successful €2 million funding round led by Enterprise Ireland, announced plans to double its team in 2023. Currently, the team consists of 14 employees based across Ireland, India, Poland, France, Spain and the Philippines.
The main challenges mentioned by Baker include finding time for essential tasks, while Ohana highlights challenges related to technology development, market fit and business model alignment. The team is working on maintaining high standards of security, compliance and innovation as the platform scales to meet customer expectations. Despite growth, Baker states that they are not currently interested in raising additional investment.
Source: Silicon Republic
